Cargando…
The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma
Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized. However, limited evidence concerning affecting factors in large interindividual variability of the pharmacokinetics of mitotane is available. To a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281498/ https://www.ncbi.nlm.nih.gov/pubmed/35847963 http://dx.doi.org/10.3389/fonc.2022.919027 |
_version_ | 1784746894168162304 |
---|---|
author | Liu, Xin Shang, Junmei Fu, Qiang Lu, Lin Deng, Jianhua Tang, Yan Li, Jiantao Mei, Dan Zhang, Bo Zhang, Shuyang |
author_facet | Liu, Xin Shang, Junmei Fu, Qiang Lu, Lin Deng, Jianhua Tang, Yan Li, Jiantao Mei, Dan Zhang, Bo Zhang, Shuyang |
author_sort | Liu, Xin |
collection | PubMed |
description | Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized. However, limited evidence concerning affecting factors in large interindividual variability of the pharmacokinetics of mitotane is available. To address this question, a retrospective analysis was performed on ACC Chinese patients treated with mitotane for more than 3 months. Mitotane plasma trough concentrations were detected at the steady state, and CYP2B6, CYP3A4, and pregnane X receptor (PXR) polymorphisms were genotyped. After examining homogeneous pharmacologic data, we restricted the analyses to 36 patients that received mitotane for a median (interquartile range, IQR) of 9 months (5.00–22.50) with a median dose of 2 g/day (2.00–2.50). As a result, drug exposure was significantly influenced by the cumulative dose of mitotane, and CYP2B6 516GG and CYP2B6 26570CC were at high risk to be below the therapeutic range of mitotane. No association was found between mitotane concentrations with CYP3A4 or PXR polymorphism. Our data firstly indicated that the cumulative dose of mitotane and polymorphisms of CYP2B6 516 and CYP2B6 26570 might significantly affect mitotane plasma trough concentrations in Chinese ACC patients. |
format | Online Article Text |
id | pubmed-9281498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92814982022-07-15 The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma Liu, Xin Shang, Junmei Fu, Qiang Lu, Lin Deng, Jianhua Tang, Yan Li, Jiantao Mei, Dan Zhang, Bo Zhang, Shuyang Front Oncol Oncology Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized. However, limited evidence concerning affecting factors in large interindividual variability of the pharmacokinetics of mitotane is available. To address this question, a retrospective analysis was performed on ACC Chinese patients treated with mitotane for more than 3 months. Mitotane plasma trough concentrations were detected at the steady state, and CYP2B6, CYP3A4, and pregnane X receptor (PXR) polymorphisms were genotyped. After examining homogeneous pharmacologic data, we restricted the analyses to 36 patients that received mitotane for a median (interquartile range, IQR) of 9 months (5.00–22.50) with a median dose of 2 g/day (2.00–2.50). As a result, drug exposure was significantly influenced by the cumulative dose of mitotane, and CYP2B6 516GG and CYP2B6 26570CC were at high risk to be below the therapeutic range of mitotane. No association was found between mitotane concentrations with CYP3A4 or PXR polymorphism. Our data firstly indicated that the cumulative dose of mitotane and polymorphisms of CYP2B6 516 and CYP2B6 26570 might significantly affect mitotane plasma trough concentrations in Chinese ACC patients. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9281498/ /pubmed/35847963 http://dx.doi.org/10.3389/fonc.2022.919027 Text en Copyright © 2022 Liu, Shang, Fu, Lu, Deng, Tang, Li, Mei, Zhang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Xin Shang, Junmei Fu, Qiang Lu, Lin Deng, Jianhua Tang, Yan Li, Jiantao Mei, Dan Zhang, Bo Zhang, Shuyang The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma |
title | The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma |
title_full | The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma |
title_fullStr | The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma |
title_full_unstemmed | The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma |
title_short | The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma |
title_sort | effects of cumulative dose and polymorphisms in cyp2b6 on the mitotane plasma trough concentrations in chinese patients with advanced adrenocortical carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281498/ https://www.ncbi.nlm.nih.gov/pubmed/35847963 http://dx.doi.org/10.3389/fonc.2022.919027 |
work_keys_str_mv | AT liuxin theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT shangjunmei theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT fuqiang theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT lulin theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT dengjianhua theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT tangyan theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT lijiantao theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT meidan theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT zhangbo theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT zhangshuyang theeffectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT liuxin effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT shangjunmei effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT fuqiang effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT lulin effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT dengjianhua effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT tangyan effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT lijiantao effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT meidan effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT zhangbo effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma AT zhangshuyang effectsofcumulativedoseandpolymorphismsincyp2b6onthemitotaneplasmatroughconcentrationsinchinesepatientswithadvancedadrenocorticalcarcinoma |